Clinical Medicine Insights: Oncology

Management Options in Advanced Prostate Cancer: What is the Role for Sipuleucel-T?

Submit a Paper

Clinical Medicine Insights: Oncology 2011:5 325-332

Consise Review

Published on 20 Oct 2011

DOI: 10.4137/CMO.S5977

Further metadata provided in PDF

Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Oncology

The Editor-in-Chief has endorsed this article

Therapeutic advances changed dramatically in 2010 with the U.S. FDA approval of the autologous cellular immunotherapy sipuleucel-T for the treatment of men with asymptomatic or minimally symptomatic metastatic CRPC. This is an updated review on the data regarding therapeutic options with particular focus on the emerging strategies for incorporating sipuleucel-T into this changing landscape.

Total Article Views Page Views PDF Views Totals
3,344 PubMed 831 358 1,189
SAGE   2,155 2,155
  Totals 831 2,513 3,344
From  October 20, 2011 to January 24, 2017

Views by Month Total Views
      LA Pubmed
HTML   831
PDF 2,155 358
Totals 2,155 1,189

Views by Region

About Article Metrics

This service is in beta and may be incomplete or contain minor discrepancies.  We welcome feedback from users.  To tell us what you think visit the survey form.

Article metrics are calculated from a variety of sources.  These sources and their known limitations are summarised here.

Total article views and downloads by month are derived from internal data and usually also Pubmed Central data.  Internal data is recorded in accordance with Project COUNTER Release 3, which is used by many publishers to ensure that visibility data is credible and reliable for readers.  It excludes automated search engine and archiving visits or downloads and rapid sequences of views or downloads to prevent accidental or intentional manipulation of data.  

Prior to September 2008 COUNTER data was not collected and prior to January 2011 views and downloads were not recorded separately.  Views by region are also derived from COUNTER data and because data on geographical region is not always available discrepancies may exist between quantities shown on the map and the table.

Pubmed Central data is only shown where the article is present on PMC and its PMC identifying number is recorded in our database.  Owing to PMC limitations data is updated once monthly and is not available prior to September 2010.  

What Your Colleagues Say About Clinical Medicine Insights: Oncology
It¹s been a pleasure working with Libertas Academica.  The staff are prompt and efficient, and the whole process is smooth.  After I submitted the corrections the proofs were updated and sent back within a day.  I would recommend Clinical Medicine Insights: Oncology to all the researchers in the field.
Dr Xiaolan “Alice” Fang (New York Genome Center, NY, USA)
More Testimonials

Quick Links

New article and journal news notification services